Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
US9199028B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9199028-B2 |
| Application number | US-201113521982-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 14, 2011 |
| Priority date | Jan 15, 2010 |
| Publication date | Dec 1, 2015 |
| Grant date | Dec 1, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates generally to compositions and methods for treating cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. In particular, the invention relates to the role of white blood cells, i.e. neutrophils and neutrophil-like cells, in preventing the spread of cancer from a primary tumor to secondary locations in the body. The invention provides methods for reducing or delaying the spread of metastatic cancer cells in a patient at risk for metastatic tumor development, at risk for metastatic relapse, i.e. prophylactic methods, and treating patients suffering from metastatic tumors.
First claim
Opening claim text (preview).
We claim: 1. A method, comprising, a) providing, i) a patient at risk for developing metastatic cancer, wherein said patient comprises a neutrophil, wherein said neutrophil is capable of being cytotoxic to a tumor cell; and ii) a chemokine selected from the group consisting of Chemokine (C-C motif) ligand 2, Chemokine (C-C motif) ligand 3, Chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 1, chemokine (C-X-C motif) ligand 12, chemokine (C-X-C motif) ligand 16, cap…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9199028B2 cover?
- The present invention relates generally to compositions and methods for treating cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. In particular, the invention relates to the role of white blood cells, i.e. neutrophils and neutrophil-like cells, in preventing the spread of cancer f…
- Who is the assignee on this patent?
- Granot Zvi, Benezra Robert, Sloan Kettering Inst Cancer
- What technology area does this patent fall under?
- Primary CPC classification A61K38/193. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).